Skip to main content
SpringerLink
Log in

Multifocal Hepatocellular Carcinoma: Genomic and Transcriptional Heterogeneity

  • Chapter
  • First Online:
The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases

  • 1963 Accesses

Abstract

Hepatocellular carcinoma (HCC) often presents with multiple nodules within the liver, with limited effective intervention. The high tumor heterogeneity of multifocal HCC might be the major cause of treatment failure. Studies using next-generation sequencing identify genomic and transcriptional heterogeneity among tumor nodules in multifocal HCC patients including mutational profiles, copy number alterations (CNAs), structure variations (SVs), tumor evolutionary trajectory, RNA expression patterns, and tumor immune microenvironment profiles. In addition, recent data indicate that the heterogeneity of druggable targets and immune landscape might help interpret the clinical responsiveness to targeted drugs and immunotherapy for multifocal HCC patients. Thus, a comprehensive and precise understanding of genomic and transcriptional heterogeneity is crucial to improve the treatment of patients with multifocal HCC and is particularly helpful to the development of personalized therapies. This Chapter reviews previous studies of genomic and transcriptional heterogeneity of multifocal HCC and discusses how we can leverage this information to improve the clinical management of patients with multifocal HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. International Agency For Research On Cancer WHO. Cancer today. https://gco.iarc.fr/today/home

  2. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016;46:372–90.

    Article  Google Scholar 

  3. Dong LQ, Peng LH, Ma LJ, Liu DB, Zhang S, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72:896–908.

    Article  CAS  Google Scholar 

  4. Xie DY, Fan HK, Ren ZG, Fan J, Gao Q. Identifying clonal origin of multifocal hepatocellular carcinoma and its clinical implications. Clin Transl Gastroenterol. 2019;10:e6.

    Article  Google Scholar 

  5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

    Article  CAS  Google Scholar 

  6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  Google Scholar 

  7. Crocenzi TS, El-Khoueiry AB, Yau TC, Melero I, Sangro B, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol. 2017;15:4013.

    Article  Google Scholar 

  8. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–502.

    Article  CAS  Google Scholar 

  9. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–52.

    Article  Google Scholar 

  10. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

    Article  CAS  Google Scholar 

  11. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105–17.

    CAS  PubMed  Google Scholar 

  12. Lin DC, Mayakonda A, Dinh HQ, Huang P, Lin L, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017;77:2255–65.

    Article  CAS  Google Scholar 

  13. Huang A, Zhao X, Yang XR, Li FQ, Zhou XL, et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol. 2017;67:293–301.

    Article  CAS  Google Scholar 

  14. Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol. 2017;67:1222–31.

    Article  Google Scholar 

  15. Gao Q, Wang ZC, Duan M, Lin YH, Zhou XY, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology. 2017;152:232–42.

    Article  CAS  Google Scholar 

  16. Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, et al. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 2017;66:363–73.

    Article  CAS  Google Scholar 

  17. Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun. 2017;8:4565.

    Article  CAS  Google Scholar 

  18. Xu LX, He MH, Dai ZH, Yu J, Wang JG, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019;30:990–7.

    Article  CAS  Google Scholar 

  19. Huang ML, He MH, Guo Y, Li HP, Shen SL et al. The influence of immune heterogeneity on the effectiveness of immune checkpoint inhibitors in multifocal hepatocellular carcinomas. Clin Cancer Res. 2020.

    Google Scholar 

  20. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, et al. Identification of an immune-specific class of hepatocellular carcinoma. Based Mol Features Gastroenterol. 2017;153:812–26.

    CAS  Google Scholar 

  21. Zhang Q, Lou Y, Yang J, Wang J, Feng J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019;68:2019–31.

    Article  CAS  Google Scholar 

  22. Xue R, Li R, Guo H, Guo L, Su Z, et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology. 2016;150:998–1008.

    Article  Google Scholar 

  23. Duan M, Hao J, Cui S, Worthley DL, Zhang S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res. 2018;28:359–73.

    Article  CAS  Google Scholar 

  24. Chen XP, Long X, Jia WL, Wu HJ, Zhao J, et al. Viral integration drives multifocal HCC during the occult HBV infection. J Exp Clin Cancer Res. 2019;38:261.

    Article  Google Scholar 

  25. Miao R, Luo H, Zhou H, Li G, Bu D, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014;61:840–9.

    Article  CAS  Google Scholar 

  26. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169:1327–41.

    Article  Google Scholar 

  27. Feo F, Pascale RM. Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis? Ann Transl Med. 2015;3:4.

    PubMed  PubMed Central  Google Scholar 

  28. Yin L, Li H, Li AJ, Lau WY, Pan ZY, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61:82–8.

    Article  Google Scholar 

  29. Zhao WC, Yang N, Zhu N, Zhang HB, Fu Y, et al. Patients with multiple hepatocellular carcinomas within the UCSF criteria have outcomes after curative resection similar to patients within the BCLC early-stage criteria. World J Surg. 2012;36:1811–23.

    Article  Google Scholar 

  30. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013;257:929–37.

    Article  Google Scholar 

  31. Ohkubo T, Midorikawa Y, Nakayama H, Moriguchi M, Aramaki O, et al. Liver resection of hepatocellular carcinoma in patients with portal hypertension and multiple tumors. Hepatol Res. 2018;48:433–41.

    Article  Google Scholar 

  32. Wada H, Eguchi H, Noda T, Ogawa H, Yamada D, et al. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. Surgery. 2016;160:1227–35.

    Article  Google Scholar 

  33. Liu W, Wang K, Bao Q, Sun Y, Xing BC. Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma. World J Surg Oncol. 2016;14:62.

    Article  Google Scholar 

  34. Ho MC, Huang GT, Tsang YM, Lee PH, Chen DS, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2009;16:848–55.

    Article  Google Scholar 

  35. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346–50.

    CAS  PubMed  Google Scholar 

  36. Makuuchi M. Surgical treatment for HCC – special reference to anatomical resection. Int J Surg. 2013;11(Suppl 1):S47–9.

    Article  Google Scholar 

  37. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl. 2004;10:S46–52.

    Article  Google Scholar 

  38. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908–16.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China

    Ming Kuang, Xin Liu & Guanrui Liao

  2. Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China

    Ming Kuang, Lixia Xu & Manling Huang

  3. Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China

    Ming Kuang & Sui Peng

  4. Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China

    Lixia Xu & Sui Peng

  5. Clinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China

    Sui Peng

Authors
  1. Ming Kuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lixia Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sui Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manling Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guanrui Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Kuang .

Editor information

Editors and Affiliations

  1. Emeritus Professor, The University of Tokyo, Tokyo, Japan

    Masatoshi Makuuchi

  2. National Center for Global Health and Medicine, The University of Tokyo, Tokyo, Japan

    Norihiro Kokudo

  3. “Dan Setlacec” Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania

    Irinel Popescu

  4. Emeritus Professor University Paris Cité, Paris, France

    Jacques Belghiti

  5. Department of Surgery, Seoul National University College of Medicine Seoul National University Bundang Hospital, Seoul, Korea (Republic of)

    Ho-Seong Han

  6. Nagahama City Hospital Network, Shiga, Japan

    Kyoichi Takaori

  7. Massachusetts General Hospital, Harvard Medical School, Boston, USA

    Dan G. Duda

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kuang, M., Xu, L., Peng, S., Huang, M., Liu, X., Liao, G. (2022). Multifocal Hepatocellular Carcinoma: Genomic and Transcriptional Heterogeneity. In: Makuuchi, M., et al. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-19-0063-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-0063-1_9

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-0062-4

  • Online ISBN: 978-981-19-0063-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation